FUNDAMENTAL AND CLINICAL STUDIES ON CEFOPERAZONE (T-1551)

Abstract

Cefoperazone (CPZ, T-1551), a new cephalosporin with antipseudomonal activity stability of β-lactamase, were carried out and the results obtained were as follows.
1) The antibacterial activity of CPZ against S. aureus, E. coli, Klebsiella, P. mirabilis, P.vulgaris and P. aeruginosa isolated from clinical specimens was compared with that cefazolin. Peaks of MIC distribution of CPZ against such various clinical isolates were 1.56, 0.2-3.13, 0.39, 1.56, 0.78 and 3.13 μg/ml at a lower inoculum size, respectively.
The antibacterial activity of CPZ against Klebsiella, P. mirabilis, P. vulgaris isolated from clinical specimens was more excellent than that of cefazolin, and against S. aureusit was inferior to that of cefazolin. Against E. coli, CPZ showed generally stronger activity than cefazolin, but in part there were a few nonsensitive strains to CPZ.
The antibacterial activity of CPZ was influenced by the inoculum size and the antibacterial activity decreased with the increase of inoculum size, especially against E. coli and P. aeruginosa.
2) CPZ was administered to one case with sepsis, two cases with infected lung cancer, one case with liver abscess, one case with pyelonephritis and one case with miliary tuberculosis, totally six cases, at a daily dose of 2-6 g for 4-29 days by intravenous drip infusion.
The clinical effects obtained were excellent in one case, good in two cases and poor in two cases with infected lung cancer, and one case with miliary tuberculosis was excluded by reason of unsuitability for CPZ therapy.
Side effects noted were fever in one case and rash with eosinophilia in one case.